Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CRNX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Crinetics Pharmaceuticals Inc

CRNX
Current price
31.93 USD -0.06 USD (-0.19%)
Last closed 31.99 USD
ISIN US22663K1079
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 996 826 368 USD
Yield for 12 month -41.02 %
1Y
3Y
5Y
10Y
15Y
CRNX
21.11.2021 - 28.11.2021

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 6055 Lusk Boulevard, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

72.67 USD

P/E Ratio

Dividend Yield

Financials CRNX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 039 000 USD

Last Year

+4 013 000 USD

Current Quarter

+361 000 USD

Last Quarter

Current Year

-1 746 000 USD

Last Year

+4 013 000 USD

Current Quarter

+361 000 USD

Last Quarter

EBITDA -373 494 016 USD
Operating Margin TTM -30 860.11 %
Price to Earnings
Return On Assets TTM -20.13 %
PEG Ratio
Return On Equity TTM -30.84 %
Wall Street Target Price 72.67 USD
Revenue TTM 760 000 USD
Book Value 13.41 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -43.60 %
Dividend Yield
Gross Profit TTM -262 295 008 USD
Earnings per share -3.80 USD
Diluted Eps TTM -3.80 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2 375.49
Price Sales TTM 3 943.19
Enterprise Value EBITDA -13.40
Price Book MRQ 2.42

Technical Indicators CRNX

For 52 Weeks

24.10 USD 62.53 USD
50 Day MA 31.19 USD
Shares Short Prior Month 10 321 299
200 Day MA 41.51 USD
Short Ratio 13.49
Shares Short 10 821 713
Short Percent 12.54 %